Cardiovascular Disease

Study shows rimonabant improves cardiometabolic risk factors in obese patients

Published in Obesity and Diabetes Week, December 12th, 2005

Sanofi-aventis announced that the results of the Rio-Lipids trial, published in The New England Journal of Medicine, showed that obese patients on rimonabant 20mg once daily experienced a significant improvement in a range of cardiometabolic risk factors that may contribute to type 2 diabetes and heart disease.

The trial evaluated rimonabant in overweight or obese patients with abnormal blood lipids (high triglycerides and/or high total cholesterol/HDL-cholesterol ratios) . Improvements included a reduction in triglyceride levels and increases in HDL-cholesterol (good cholesterol).

There were also reductions in waist circumference and body...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry